Systems pharmacology is a novel framework for drug research that models traditional and innovative pharmacological parameters and provides the overall efficacy and safety profile of a drug across body systems and complex, non-linear, molecular interactions. Lithium chloride, a pharmacological compound approved for the therapy of psychiatric disorders, represents a poorly explored compound for the treatment of Alzheimer's disease (AD). Lithium has been shown to reduce downstream effects associated with the aberrant overactivation of certain molecular pathways, such as glycogen synthase kinase 3 subunit β (GSK3-β)-related pathways, involved in AD-related pathophysiology. It seems that overactivation and overexpression of GSK3-β lead to an impairment of long-term potentiation and amyloid-β induced neurotoxicity that can be normalized using lithium. Moreover, a growing body of evidence has demonstrated that lithium's GSK3-β inhibitory effect prevents tau phosphorylation in mouse models of tauopathies. Clinical data have been inconclusive, partly due to methodological limitations. The lack of studies exploring the dynamics of protein misfolding in AD and investigating the specific tau-isoforms appearing prior to the accumulation of neurofibrillary tangles calls for new and optimized clinical trials. Advanced computer modeling based on a formal implementation of quantitative parameters and basic enzymatic insights into a mechanism-based model would present a good start to tackle these non-linear interactions. This innovative approach will pave the way for developing "molecularly" biomarker-guided targeted therapies, i.e., treatments specifically adapted ("tailored") to the individual, consistently with the primary objectives and key conceptual points of precision medicine and precision pharmacology.

Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., et al. (2019). Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. JOURNAL OF ALZHEIMER'S DISEASE, 69(3), 615-629 [10.3233/JAD-190197].

Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective

Mango, Dalila;Nisticò, Robert;
2019-01-01

Abstract

 Systems pharmacology is a novel framework for drug research that models traditional and innovative pharmacological parameters and provides the overall efficacy and safety profile of a drug across body systems and complex, non-linear, molecular interactions. Lithium chloride, a pharmacological compound approved for the therapy of psychiatric disorders, represents a poorly explored compound for the treatment of Alzheimer's disease (AD). Lithium has been shown to reduce downstream effects associated with the aberrant overactivation of certain molecular pathways, such as glycogen synthase kinase 3 subunit β (GSK3-β)-related pathways, involved in AD-related pathophysiology. It seems that overactivation and overexpression of GSK3-β lead to an impairment of long-term potentiation and amyloid-β induced neurotoxicity that can be normalized using lithium. Moreover, a growing body of evidence has demonstrated that lithium's GSK3-β inhibitory effect prevents tau phosphorylation in mouse models of tauopathies. Clinical data have been inconclusive, partly due to methodological limitations. The lack of studies exploring the dynamics of protein misfolding in AD and investigating the specific tau-isoforms appearing prior to the accumulation of neurofibrillary tangles calls for new and optimized clinical trials. Advanced computer modeling based on a formal implementation of quantitative parameters and basic enzymatic insights into a mechanism-based model would present a good start to tackle these non-linear interactions. This innovative approach will pave the way for developing "molecularly" biomarker-guided targeted therapies, i.e., treatments specifically adapted ("tailored") to the individual, consistently with the primary objectives and key conceptual points of precision medicine and precision pharmacology.
2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/14 - FARMACOLOGIA
English
Alzheimer’s disease; GSK3; lithium; neurotoxicity; post-translational modification; precision medicine; systems pharmacology; tau
Hampel, H., Lista, S., Mango, D., Nisticò, R., Perry, G., Avila, J., et al. (2019). Lithium as a Treatment for Alzheimer's Disease: The Systems Pharmacology Perspective. JOURNAL OF ALZHEIMER'S DISEASE, 69(3), 615-629 [10.3233/JAD-190197].
Hampel, H; Lista, S; Mango, D; Nisticò, R; Perry, G; Avila, J; Hernandez, F; Geerts, H; Vergallo, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Hampel_Lithium_J Alzheimers Dis. 2019;69(3)615-629.pdf

solo utenti autorizzati

Descrizione: Lithium as a Treatment for Alzheimer's Disease
Licenza: Copyright dell'editore
Dimensione 320.5 kB
Formato Adobe PDF
320.5 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/214975
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 41
  • ???jsp.display-item.citation.isi??? 40
social impact